2021 kicked off with surface innovation made available for even more clinicians. Following several years’ scientific research and gradual roll-out in Europe and beyond, the anodized Xeal™ abutments and TiUltra™ implants were officially launched across the entire United States.
After over two decades’ of the most well-documented implant surface, TiUnite, its clinically proven anodization technique has been tailored for tissue integration at every level. In 2021, the US entered the Mucointegration™ era.
“I have envisioned and hope for an implant surface like Nobel Biocare’s TiUltra for many years. I am excited to use this innovative design to enhance my patients’ long-term implant success."
Dr. Chad Cravatta, Arizona, US
"I personally have been utilizing both TiUltra™ and Xeal™ for my Nobel Biocare implants over the last year-and-a-half. It’s been fantastic. We’ve had great results overall and I’m not looking back. We are completely converted over to using these surfaces now. I’ve got over 1,000 of these implants in place and it’s been fantastic seeing the results..” Dr. Bobby Birdi, Canada
“The hydrophilic properties and chemistry of the Xeal abutments represent very important pieces in fulfilling the Mucointegration™ process. Now we have ideal surfaces to complement our clinical procedures.”
Dr. Giacomo Fabbri, Italy
Clinical studies are well under way, with preliminary results published including studies by Drs. Giacomo Fabbri and Giorgio Ban and one-year follow-up examining the surfaces with the All-on-4® treatment concept clinic by Drs. Ana Ferro and Miguel Nobre. In addition, a randomized and controlled clinical study, Xeal™ demonstrated a fourfold reduction in cultivable bacteria after six months as well as a statistically significant increase in keratinized mucosa growth.
Watch this space for more clinical findings to emerge in 2022.